RhoGDI signaling provides targets for cancer therapy.

Abstract

Rho GDP-Dissociation Inhibitors (RhoGDIs) are important regulators of the Rho family of small GTPases. The expression of RhoGDIs is altered in a variety of cancers and they have been shown to mediate several processes during tumorigenesis and cancer progression. Using examples of RhoGDI-mediated signaling and expression patterns in endothelial cells as well as pancreatic, breast, and bladder cancer, the multitude of potential cancer therapeutic targets presented by a better understanding of their function is illustrated. Several novel therapeutic strategies are proposed for intervening in RhoGDI signaling, and potential complications arising from their implementation are discussed.

• Authors: Michael A Harding, Dan Theodorescu
• Journal: European journal of cancer (Oxford, England : 1990) (Eur J Cancer) Vol. 46 Issue 7 Pg. 1252-9 (May 2010) ISSN: 1879-0852 [Electronic] England
• PMID: 20347589 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Review)
• Copyright: Published by Elsevier Ltd.

Chemical References

• ARHGDIA protein, human
• Antineoplastic Agents
• Guanine Nucleotide Dissociation Inhibitors
• Neoplasm Proteins
• rho Guanine Nucleotide Dissociation Inhibitor alpha
• rho-Specific Guanine Nucleotide Dissociation Inhibitors

Topics

• Antineoplastic Agents (pharmacology)
• Breast Neoplasms (drug therapy, metabolism)
• Female
• Guanine Nucleotide Dissociation Inhibitors (antagonists & inhibitors, metabolism)
• Humans
• Neoplasm Proteins (antagonists & inhibitors, metabolism)
• Neoplasms (drug therapy, metabolism)
• Pancreatic Neoplasms (drug therapy, metabolism)
• Signal Transduction (drug effects, physiology)
• Urinary Bladder Neoplasms (drug therapy, metabolism)
• rho Guanine Nucleotide Dissociation Inhibitor alpha
• rho-Specific Guanine Nucleotide Dissociation Inhibitors